It’s time that we open our collective eyes to the realities of most breast cancer screening programs: they fail to engage the majority of women.
Breast cancer screening programs that rely solely upon one the widespread availability of a single, poorly adopted modality, fail women. Without widespread availability and adoption, there’s no significant impact upon the health of populations.
To be very clear: mammograms have saved hundreds of thousands of lives and we are in no way “anti-mammogram.” Instead, we are “pro-reality,” and that reality is that the adoption of mammography by women in most countries is very poor.
It’s time for and additional modality, one that can be made easily available and that women will adopt. That modality is Bexa.
undetected/untreated
DCIS - "stage 0"
unscreened but treated invasive
breast cancer - stages I-IV
Committing to offer only mammograms doesn’t make humanitarian sense, clinical sense, or financial sense. What does make sense is to also offer a modality - Bexa - that can engage the women that won’t or can’t have mammograms.
Further, the majority of invasive breast cancers present as an abnormal mass. For abnormal masses, Bexa has a higher sensitivity and lower need for follow-on studies than any other technology. Learn more about the detailed clinical performance of Bexa here.
In every culture women have told us clearly that clinics and hospitals are intimidating to healthy women, and are a barrier to adoption. Bexa can be deployed anywhere a woman can be examined in private.
Bexa is an excellent offering for primary care, community-based or retail locations. If you or your organization are interested in offering Bexa examinations, contact our international commercial team.
High resolution breast elastography
to identify and document abnormal masses.